From the May 2020 issue of HealthCare Business News magazine
PET/CT imaging systems are the third-most-active market segment, which includes 16 to 40 slice systems and 64 to 128 slice systems. There has been an equal amount of activity within these two markets, with Siemens and GE being the most active vendors.
In the 16- to 40-slice market. Siemens has two offerings that clients have requested the most: the Biograph mCT-s (40) and the Biograph Horizon, with APP of $1.33 million and $1.11 million, respectively. GE’s Discovery MI Digital Ready imaging system has an APP of $1.7 million and its Discovery IQ 3 Ring system has an APP of $985k.
Quality remanufactured Certified Centrifuges at Great prices! Fully warranted and backed by a company you can trust! Call or click for a free quote today! www.Centrifugestore.com 800-457-7576
The 64- to 128-slice market has three vendors who are most active in PET/CT: Siemens, GE, and Philips. There has been a slow increase in the Vereos and Ingenuity PET/CT offerings from Philips. The APP for the Vereos system is $2.37 million, and the Ingenuity has an APP of $1.23 million. The market reflects activity in three offerings from Siemens: the Biograph mCT-s (64) system with an AP of $1.05 million, the Biograph Vision 600 with an APP of $2.79 million, and the Biograph Vision 450 with an APP of $1.93 million. Two GE systems — the Discovery MI 3 Ring and the Discovery MI 5 Ring — have APPs of $2.46 million and $2.99 million, respectively.
Edward Rodriguez, BS, R.T.(R) (MR)
Only time will tell the extent to which vendors will be impacted by COVID-19 and how the growth in market projections will change. As most are aware, the business side of healthcare will greatly be affected as both the hospitals and vendors do everything possible to improve the patient’s outcome. Hospitals and clinics will continue to build on their relationships with vendors and strengthen their partnerships. There are several Molecular Imaging systems at different price points for healthcare facilities to consider. These systems can be configured to the client’s current and future needs. A follow-up study in 6 to 12 months would be ideal to better visualize how much COVID-19 impacted the Molecular Imaging market and any noticeable change in a particular market segment.
About the author: Edward Rodriguez is a clinical advisor for TractManager.Back to HCB News